BACKGROUND: We assessed the impact of 12 years of pneumococcal conjugate vaccine (PCV7) use on pneumococcal nasopharyngeal carriage and serotype-specific invasive disease potential among Native Americans. METHODS: Families were enrolled in a carriage study from 2006 to 2008; nasopharyngeal specimens and risk factor information were collected monthly for 7 visits. Pneumococcal carriage prevalence was compared with that before (1998-2000) and during (2001-2002) PCV7 introduction. We compared invasive disease incidence and carriage prevalence before and after PCV7 introduction to estimate changes in serotype-specific invasive potential. RESULTS: We enrolled 1077 subjects from 302 households. There was an absolute reduction in carriage prevalence of 8.0% (95% confidence interval [CI], 4.5%-11.4%) in children aged <5 years and 3.1% (95% CI, 1.1%-5.1%) in adults. In children aged <5 years, vaccine-serotype carriage prevalence decreased by 22.8% (95% CI, 20.1%-25.3%), and nonvaccine serotype (NVT) increased by 15.9% (95% CI, 12.4%-19.3%). No significant change was detected in serotype-specific invasive potential after PCV7 introduction. CONCLUSIONS: Pneumococcal carriage prevalence decreased in all ages since PCV7 introduction; vaccine-serotype carriage has been nearly eliminated, whereas the prevalence of NVT carriage has increased. The increase in the NVT invasive disease rate seems to be proportional to the increase in colonization prevalence.
BACKGROUND: We assessed the impact of 12 years of pneumococcal conjugate vaccine (PCV7) use on pneumococcal nasopharyngeal carriage and serotype-specific invasive disease potential among Native Americans. METHODS: Families were enrolled in a carriage study from 2006 to 2008; nasopharyngeal specimens and risk factor information were collected monthly for 7 visits. Pneumococcal carriage prevalence was compared with that before (1998-2000) and during (2001-2002) PCV7 introduction. We compared invasive disease incidence and carriage prevalence before and after PCV7 introduction to estimate changes in serotype-specific invasive potential. RESULTS: We enrolled 1077 subjects from 302 households. There was an absolute reduction in carriage prevalence of 8.0% (95% confidence interval [CI], 4.5%-11.4%) in children aged <5 years and 3.1% (95% CI, 1.1%-5.1%) in adults. In children aged <5 years, vaccine-serotype carriage prevalence decreased by 22.8% (95% CI, 20.1%-25.3%), and nonvaccine serotype (NVT) increased by 15.9% (95% CI, 12.4%-19.3%). No significant change was detected in serotype-specific invasive potential after PCV7 introduction. CONCLUSIONS:Pneumococcal carriage prevalence decreased in all ages since PCV7 introduction; vaccine-serotype carriage has been nearly eliminated, whereas the prevalence of NVT carriage has increased. The increase in the NVT invasive disease rate seems to be proportional to the increase in colonization prevalence.
Authors: Angela B Brueggemann; Timothy E A Peto; Derrick W Crook; Jay C Butler; Karl G Kristinsson; Brian G Spratt Journal: J Infect Dis Date: 2004-08-25 Impact factor: 5.226
Authors: Eugene V Millar; Katherine L O'Brien; James P Watt; Melinda A Bronsdon; Jean Dallas; Cynthia G Whitney; Raymond Reid; Mathuram Santosham Journal: Clin Infect Dis Date: 2006-05-18 Impact factor: 9.079
Authors: In Ho Park; David G Pritchard; Rob Cartee; Angela Brandao; Maria Cristina C Brandileone; Moon H Nahm Journal: J Clin Microbiol Date: 2007-01-31 Impact factor: 5.948
Authors: Katherine L O'Brien; Jana Shaw; Robert Weatherholtz; Raymond Reid; James Watt; Janne Croll; Ron Dagan; Alan J Parkinson; Mathuram Santosham Journal: Am J Epidemiol Date: 2004-08-01 Impact factor: 4.897
Authors: Cynthia G Whitney; Monica M Farley; James Hadler; Lee H Harrison; Nancy M Bennett; Ruth Lynfield; Arthur Reingold; Paul R Cieslak; Tamara Pilishvili; Delois Jackson; Richard R Facklam; James H Jorgensen; Anne Schuchat Journal: N Engl J Med Date: 2003-05-01 Impact factor: 91.245
Authors: Sheldon L Kaplan; Edward O Mason; Ellen R Wald; Gordon E Schutze; John S Bradley; Tina Q Tan; Jill A Hoffman; Laurence B Givner; Ram Yogev; William J Barson Journal: Pediatrics Date: 2004-03 Impact factor: 7.124
Authors: Jennifer R Scott; Jason Hinds; Katherine A Gould; Eugene V Millar; Raymond Reid; Mathuram Santosham; Katherine L O'Brien; William P Hanage Journal: J Infect Dis Date: 2012-04-25 Impact factor: 5.226
Authors: Amelieke J H Cremers; Jonneke Lut; Peter W M Hermans; Jacques F Meis; Marien I de Jonge; Gerben Ferwerda Journal: Clin Vaccine Immunol Date: 2014-04-23
Authors: Charlene A Wong; Francine C Gachupin; Robert C Holman; Marian F MacDorman; James E Cheek; Steve Holve; Rosalyn J Singleton Journal: Am J Public Health Date: 2014-04-22 Impact factor: 9.308
Authors: Taj Azarian; Lindsay R Grant; Maria Georgieva; Laura L Hammitt; Raymond Reid; Stephen D Bentley; David Goldblatt; Mathuran Santosham; Robert Weatherholtz; Paula Burbidge; Novalene Goklish; Claudette M Thompson; William P Hanage; Kate L O'Brien; Marc Lipsitch Journal: J Infect Dis Date: 2017-03-01 Impact factor: 5.226
Authors: Daniel M Weinberger; Dana T Bruden; Lindsay R Grant; Marc Lipsitch; Katherine L O'Brien; Stephen I Pelton; Elisabeth A M Sanders; Daniel R Feikin Journal: Am J Epidemiol Date: 2013-09-07 Impact factor: 4.897
Authors: Theano Lagousi; John Routsias; Christina Piperi; Athanassios Tsakris; George Chrousos; Maria Theodoridou; Vana Spoulou Journal: J Biol Chem Date: 2015-09-22 Impact factor: 5.157
Authors: Daniel M Weinberger; Lindsay R Grant; Claudia A Steiner; Robert Weatherholtz; Mathuram Santosham; Cécile Viboud; Katherine L O'Brien Journal: Clin Infect Dis Date: 2013-11-03 Impact factor: 9.079
Authors: Daniel M Weinberger; Lindsay R Grant; Robert C Weatherholtz; Joshua L Warren; Katherine L O'Brien; Laura L Hammitt Journal: Am J Epidemiol Date: 2016-05-02 Impact factor: 4.897